Athira Pharma Rebounds from Alzheimer’s Setbacks with $90 Million Breast Cancer Deal
Athira Pharma is executing a dramatic strategic shift, pivoting its primary focus from Alzheimer's disease to oncology following years marked ...
Tag: Phase 3 de-risking
Popular News
-
Zillow Eliminates 200 Positions Following Annual Performance Reviews
-
Seattle Police Arrest 18-Year-Old After Drive-By Shooting and High-Speed Chase
-
Iran Warns US Strike Would Ignite Broader Middle East Conflict
-
Firefighters Discover Body While Battling Des Moines Residential Blaze
-
Amazon and T-Mobile Cut Nearly 2,600 Jobs in Bellevue as Tech Downsizing Accelerates
